Investing in AIDD

AIDD seeks CHF4 million in funding for the next two years of operations. 

We estimate that up to 50% of financing will be raised via non-dilutive sources, for example Swiss federal "CTI" grants, and other national schemes for financing research as well as European sources like Eurostars and Horizon 2020. As necessary, AIDD will complement non-dilutive sources of funding with risk-sharing collaborations with other insititutes for drug discovery and industrial partners.

Investors who kick-start AIDD will receive shares in AIDD sponsored Special Purpose Vehicles (SPV), which offer a venture-like return.

The AIDD business model is proven by other institutes for drug discovery, including the Medical Research Council Technology (MRCT); Institute for Research in Immunology and Cancer - Commercialization of Research (IRICoR); Vanderbilt Center for Neuroscience Drug Discovery (VCNDD); and Lead Discovery Center (LDC). Several such institutes already have expressed a strong interest in partnering with AIDD in order to access its differentiated technology platform.

AIDD also is actively seeking donations from individuals, philanthropic institutions and foundations that identify with the values and aspirations of our institute. 

For more information, please contact info(at)